After the tolerizing regimen, the host is withdrawn from the suppressive agents, but is able to maintain specific immune tolerance to the immunogenic epitopes present on the toleragen.
Thus, we suggest that patients whose complex aphthosis does not respond to colchicine in their initial therapeutic trial continue taking colchicine when dapsone is added to the regimen.
"The difference in treatment effects between the regimens may be related to the speed with which maximal serum levels of anti–interleukin-12 are attained or sustained," the authors write.
Objective To evaluate the treatment of non-Hodgkin s lymphoma with combined regimen containing epirubicin as the main drug and to find an effective regimen with low toxicity.